ClinicalTrials.gov
ClinicalTrials.gov Menu

A Prospective, Observational Study to Examine the Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty' (POPPY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01737047
Recruitment Status : Active, not recruiting
First Posted : November 29, 2012
Last Update Posted : January 16, 2017
Sponsor:
Collaborators:
Gilead Sciences
Janssen, LP
ViiV Healthcare
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Imperial College London

Study Description
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this study is to identify medical conditions that may cause particular problems to individuals receiving care for HIV infection over the age of 50. In addition, as the effects and potentially the side effects, of HIV medication may change with age, this study will also investigate the association between age and differing effects of antiretroviral therapies such as treatment outcomes, side effects and the levels of drugs in blood.

Results from this study may inform future HIV treatment guidelines on how we monitor individuals with HIV infection. The results may also assist in the design of future studies for the treatment of diseases associated with ageing.


Condition or disease
HIV Positive Ageing

Detailed Description:

Multicentre, prospective, observational study over 3 years.

Our study will describe the impact of advancing age on the experience of living with HIV in England and Ireland. To address this we will establish cohorts of HIV-positive people aged >50 and <50 years as well as demographically matched HIV-negative people aged >50 years.

  1. To analyse the incidence and outcomes of co-morbidities in older-HIV-positive people and their relationship with demographic/clinical factors.
  2. To evaluate associations between antiretroviral drug concentrations and age, and to assess the potential impact of age on drug efficacy, drug-drug interactions and co-morbidities.
  3. To contribute to the development and implementation of evidence-based recommendations for the clinical monitoring of older HIV-positive patients.

2000 will be recruited in all either white or black african individuals (self reported) 1000 will be Over 50 years of age and HIV positive, 500 will be under the age of 50 and will be HIV positive and 500 will be over the age of 50 and be HIV negative.


Study Design
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Observational
Actual Enrollment : 1376 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Observational Study to Examine the Effects of Ageing on the Clinical Outcomes of People Living With HIV in England and Ireland
Study Start Date : April 2013
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : August 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Groups and Cohorts
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
HIV positive over 50 years of age

All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.

Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn
HIV positive under the age of 50

All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.

Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn
HIV negative over the age of 50
All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.


Outcome Measures
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. clinical manifestations of ageing [ Time Frame: after 2 years ]
    To analyse the incidence and outcomes of co-morbidities in older-HIV-positive people and their relationship with demographic/clinical factors.Comparison of three groups HIV+ve >50, HIV+<50 and HIV-ve >50. White or black african - analysis of demographic details and co-morbidity details collected at each visit.


Secondary Outcome Measures :
  1. variations of anti-retroviral medication associated with age. [ Time Frame: after 2 years ]
    Comparison of two groups HIV+ve >50 and HIV+ <50 measurement of blood concentrations of HIV medications

  2. to assess the potential impact of age on drug efficacy, drug-drug interactions and co-morbidities. [ Time Frame: two years ]
    Comparison of three groups HIV+ve >50, HIV+<50 and HIV-ve >50. Drug related side effects collected at each visit and also Co-morbidity details collected at each visit.


Other Outcome Measures:
  1. To contribute to the development and implementation of evidence-based recommendations for the clinical monitoring of older HIV-positive patients. [ Time Frame: after 2 years ]
    Comparison of co-morbidities in relation to age in the three groups: HIV+ve >50, HIV+ve <50 and HIV -ve >50.


Biospecimen Retention:   Samples With DNA
Blood for storage Blood (serum and plasma,) and urine samples will be collected at visits 1 and 3 stored for subsequent projects of the potential pathogenic mechanisms underlying age-related diseases. This will include assessment of vitamin-D and PTH and probably DNA analysis.

Eligibility Criteria
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
HIV positive over 50 years HIV positive between 18 and 50 years HIV negative over 50 years White Black african
Criteria

Inclusion Criteria:

Older HIV-positive cohort (n=1000):

  • documented HIV infection
  • age >50 years at study entry
  • self defined white or black African ethnicity
  • likely route of HIV acquisition via sexual exposure Either by male to male exposure if white or by heterosexual exposure if white or black African

  • able to comprehend study patient information leaflet

    -Younger HIV-positive cohort (n=500):

  • documented HIV infection
  • age <50 at study entry*
  • self defined white or black African ethnicity
  • likely route of HIV acquisition via sexual exposure Either by male to male exposure if white or by heterosexual exposure if white or black African.

  • able to comprehend study patient information leaflet

    • this group will comprise of at least 150 subjects in each of the following age groups: 20-29, 30-39, 40-49 years. Recruitment will be monitored by the Study Monitoring Team.

HIV-negative cohort (n=500):

  • documented negative HIV test at screening
  • age >50 years at study entry
  • self defined white or black African ethnicity
  • registered with a General Practitioner and gives permission for contact with that General Practitioner.

Exclusion Criteria:

  • in the opinion of the investigator, those unable or unwilling to comply with the requirements of the study
  • life expectancy less than 6 months
Contacts and Locations
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01737047


Locations
Ireland
University College Dublin School of Medicine and Medical Sciences, Mater Misericordiae University Hospital
Dublin, Ireland, 7
United Kingdom
Royal Sussex County Hospital
Brighton, Sussex, United Kingdom, BN2 5BE
Homerton University Hospital NHS Foundation Trust
London, United Kingdom, E9 6SR
Royal Free Hospital
London, United Kingdom, NW3 2QG
Kings College Hospital NHS Trust
London, United Kingdom, SE5 9RJ
Chelsea and Westminster Hospital
London, United Kingdom, SW10 9NH
St Marys Hospital NHS Trust
London, United Kingdom, W2 1NY
University College NHS Trust
London, United Kingdom, WC1E 6JB
Sponsors and Collaborators
Imperial College London
Gilead Sciences
Janssen, LP
ViiV Healthcare
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.
Investigators
Study Director: Caroline Sabine, PhD University College, London
Study Director: Alan Winston, MD Imperial College London
More Information
Go to 
Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01737047     History of Changes
Other Study ID Numbers: CRO: 1992
2012-003581-40 ( EudraCT Number )
First Posted: November 29, 2012    Key Record Dates
Last Update Posted: January 16, 2017
Last Verified: December 2016

Keywords provided by Imperial College London:
HIV
Ageing

Additional relevant MeSH terms:
HIV Seropositivity
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
 Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action